| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 09.05. | Sosei Group reports Q1 results | 1 | Seeking Alpha | ||
| 01.04. | Nxera Pharma is the New Name for Sosei Group | 137 | GlobeNewswire (Europe) | New name expresses the Company's vision to lead the next era of medicine - from Japan, for Japan, and by extension, to the world - and its mission to accelerate the development of life-changing medicines... ► Artikel lesen | |
| 27.03. | Sosei Group Corporation: Sosei Heptares Confirms Re-election of its Board and Executive Management Team and the Approval of Change of Company Name to Nxera Pharma | 104 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 27 March 2024 - Sosei Group Corporation ("the Company"; TSE: 4565) announces that the re-election of its Board of Directors and Executive Officers was approved at the... ► Artikel lesen | |
| 27.03. | SOSEI GROUP CORPORATION: CHANGE IN ISSUER NAME::MANDATORY | - | SGX Company Announcements | ||
| 21.03. | Sosei Group Regains Full Ownership From GSK Of Clinic-Ready GPR35 Agonist For Inflammatory Bowel Disease | 504 | AFX News | LONDON (dpa-AFX) - Sosei Group Corp. said it has regained full ownership from GSK of HTL0027477 (formerly GSK4381406), a clinic-ready, highly selective, first-in-class, oral GPR35 agonist in... ► Artikel lesen | |
| 21.03. | Sosei Group Corporation: Sosei Heptares Doses First Subject in Phase 1 Trial with HTL0033744, an EP4 Agonist for Inflammatory Bowel Disease | 90 | GlobeNewswire (Europe) | HTL0033744 has been designed by Sosei Heptares to promote mucosal healing and resolve inflammation in people with IBD Tokyo, Japan and Cambridge, UK, 21 March 2024 - Sosei Group Corporation ("Sosei... ► Artikel lesen | |
| 21.03. | Sosei Group Corporation: Sosei Heptares Regains Full Ownership from GSK of HTL0027477, a Clinic-ready, First-in-Class Oral GPR35 Agonist for Inflammatory Bowel Disease | 102 | GlobeNewswire (Europe) | GPR35 is a novel target with an established genetic association to IBDUK regulatory approval received to commence first-in-human studiesReturn of rights follows change in immunology research strategy... ► Artikel lesen | |
| 14.03. | SOSEI GROUP CORPORATION: ISSUER'S EARLY REDEMPTION (CALL OPTION)::MANDATORY | - | SGX Company Announcements | ||
| 11.03. | Sosei Group Corporation: Boehringer Ingelheim and Sosei Heptares join forces to develop first-in-class treatments targeting all symptoms of schizophrenia | 175 | GlobeNewswire (Europe) | Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive... ► Artikel lesen | |
| 06.03. | Sosei Group Corporation: Sosei Heptares to receive US$2.5 million milestone payment from Formosa Pharmaceuticals | 690 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 6 March 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565) announces that Formosa Pharmaceuticals, Inc. ("Formosa") has received approval... ► Artikel lesen | |
| 16.02. | Sosei Group Corporation: Sosei Group: Notice of Change of Corporate Name to Nxera Pharma and Change of Location of Head Office | 203 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 16 February 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565), today announces that at a meeting held on 15 February 2024, its Board of... ► Artikel lesen | |
| 13.02. | Sosei Group reports FY results | 1 | Seeking Alpha | ||
| 13.02. | SOSEI GROUP CORPORATION: FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::FULL YEARLY RESULTS | - | SGX Company Announcements | ||
| 13.02. | Sosei Group Corporation: Sosei Heptares Operational Highlights and Consolidated Results for 12 Months ended 31 December 2023 | 167 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 13 February 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565) provides an update on operational activities and reports its consolidated... ► Artikel lesen | |
| 22.01. | Sosei Group Corporation: Sosei Heptares Webinar Presentation for FY2023 Financial Results | 2 | GlobeNewswire (USA) | ||
| 05.01. | Sosei Group Corporation: Sosei Group Announces Appointment of Experienced Pharmaceutical Executive Toshihiro Maeda as Chief Operating Officer | 546 | GlobeNewswire (Europe) | Tokyo, Japan and Cambridge, UK, 5 January 2024 - Sosei Group Corporation ("Sosei Heptares" or "the Company"; TSE: 4565) today announces the appointment of Mr. Toshihiro Maeda as Chief Operating Officer... ► Artikel lesen | |
| 21.12.23 | Sosei Group Corporation: Sosei Heptares to Present at 42nd Annual J.P. Morgan Healthcare Conference | 1 | GlobeNewswire (USA) | ||
| 15.12.23 | SOSEI GROUP CORPORATION: GENERAL ANNOUNCEMENT::RESULT OF REPURCHASE OF OUTSTANDING CONVERTIBLE BONDS | - | SGX Company Announcements | ||
| 07.12.23 | Sosei Group Corporation: Sosei Group Announces Marketing Approval for PIVLAZ (clazosentan sodium) 150 mg in South Korea | 209 | GlobeNewswire (Europe) | PIVLAZ, a new drug for prevention of Cerebral Vasospasm in patients with Aneurysmal Subarachnoid Hemorrhage (aSAH), approved in South KoreaPIVLAZ will become commercially available in South Korea... ► Artikel lesen | |
| 06.12.23 | Sosei Group Corporation: Sosei Heptares' Partner Neurocrine Biosciences Confirms its Plans to Evaluate Two New Muscarinic Agonist Candidates in Phase 1 Clinical Studies | 239 | GlobeNewswire (Europe) | Both NBI-1117569 (an M4-preferring agonist) and NBI-1117567 (an M1-preferring agonist) are investigational, oral, muscarinic agonists discovered by Sosei Heptares that may have the potential to treat... ► Artikel lesen |
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NEL | 3.888 |
| EVOTEC | 2.782 |
| NVIDIA | 2.521 |
| VOLKSWAGEN | 2.154 |
| BAYER | 1.779 |
| TUI | 1.742 |
| SALESFORCE | 1.640 |
| GAMESTOP | 1.418 |
| PLUG POWER | 1.265 |
| DELL TECHNOLOGIES | 1.172 |
| BIONTECH | 1.111 |
| BYD | 1.048 |
| AIXTRON SE | 1.000 |
| RHEINMETALL | 914 |
| UIPATH | 882 |
| DEUTSCHE LUFTHANSA | 822 |
| SUPER MICRO COMPUTER | 733 |
| JINKOSOLAR | 713 |
| SIEMENS ENERGY | 666 |
| DEUTSCHE BANK | 644 |
| PALANTIR TECHNOLOGIES | 633 |
| TESLA | 601 |
| HELLOFRESH | 596 |
| MERCEDES-BENZ | 591 |
| BASF | 585 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
